

Publikationsliste 2010

Originalpublikationen

1. Achermann Y, Vogt M, Spormann C, Kolling C, Remschmidt C, Wust J, Simmen B, Trampuz A. Characteristics and outcome of 27 elbow periprosthetic joint infection: Results from a 14-year cohort study of 358 elbow prostheses. *Clin Microbiol Infect* 2010. [Epub ahead of print].
2. Alizon S, von Wyl V, Stadler T, Kouyos RD, Yerly S, Hirschel B, Boni J, Shah C, Klimkait T, Furrer H, Rauch A, Vernazza PL, Bernasconi E, Battegay M, Burgisser P, Telenti A, Gunthard HF, Bonhoeffer S. Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. *PLoS Pathog* 2010;6 e1001123.
3. Althaus CF, Gianella S, Rieder P, von Wyl V, Kouyos RD, Niederost B, Schmid A, Metzner KJ, Joos B, Gunthard HF, Fischer M. Rational design of HIV-1 fluorescent hydrolysis probes considering phylogenetic variation and probe performance. *J Virol Methods* 2010;165:151-60.
4. Audige A, Schlaepfer E, von Wyl V, Miller RC, Vernazza P, Nadal D, Speck RF. B cells from HIV-infected patients with primary central nervous system lymphoma display an activated phenotype and have a blunted TNF-alpha response to TLR9 triggering. *AIDS Res Hum Retroviruses* 2010;26:1063-74.
5. Audige A, Taffe P, Rickenbach M, Battegay M, Vernazza P, Nadal D, Speck RF. Low postseroconversion CD4 count and rapid decrease of CD4 density identify HIV+ fast progressors. *AIDS Res Hum Retroviruses* 2010;26:997-1005.
6. Baker JV, Neuhaus J, Duprez D, Kuller LH, Tracy R, Belloso WH, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon DE, Paton NI, Neaton JD. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. *J Acquir Immune Defic Syndr* 2010 [Epub ahead of print].
7. Barnes E, Flanagan P, Brown A, Robinson N, Brown H, McClure M, Oxenius A, Collier J, Weber J, Gunthard HF, Hirschel B, Fidler S, Phillips R, Frater J. Failure to detect xenotropic murine leukemia virus-related virus in blood of individuals at high risk of blood-borne viral infections. *J Infect Dis* 2010;202:1482-5.
8. Bischoff-Ferrari HA, Dawson-Hughes B, Platz A, Orav EJ, Stahelin HB, Willett WC, Can U, Egli A, Mueller NJ, Looser S, Bretscher B, Minder E, Vergopoulos A, Theiler R. Effect of high-dosage cholecalciferol and extended physiotherapy on complications after hip fracture: a randomized controlled trial. *Arch Intern Med* 2010;170:813-20.
9. Bucher HC, Rickenbach M, Young J, Glass TR, Vallet Y, Bernasconi E, Cavassini M, Fux C, Schiffer V, Vernazza P, Weber R, Battegay M. Randomized trial of a computerized coronary heart disease risk assessment

- tool in HIV-infected patients receiving combination antiretroviral therapy. *Antivir Ther* 2010;15:31-40.
10. Casado C, Colombo S, Rauch A, Martinez R, Gunthard HF, Garcia S, Rodriguez C, Del Romero J, Telenti A, Lopez-Galindez C. Host and viral genetic correlates of clinical definitions of HIV-1 disease progression. *PLoS One* 2010;5:e11079.
 11. Chow OA, von Kockritz-Blickwede M, Bright AT, Hensler ME, Zinkernagel AS, Cogen AL, Gallo RL, Monestier M, Wang Y, Glass CK, Nizet V. Statins enhance formation of phagocyte extracellular traps. *Cell Host Microbe* 2010;8:445-54.
 12. Colombo C, Masserey V, Ruef C. Incidence of needlestick injuries and other sharps exposures in Swiss acute care hospitals: Results of a sentinel surveillance study. *J Hosp Infect* 2010. [Epub ahead of print].
 13. Curkovic I, Luthi B, Franzen D, Ceschi A, Rudiger A, Corti N. Trimethoprim/Sulfamethoxazole pharmacokinetics in two patients undergoing continuous venovenous hemodiafiltration. *Ann Pharmacother* 2010;44:1669-72.
 14. Cusini A, Rampini SK, Bansal V, Ledergerber B, Kuster SP, Ruef C, Weber R. Different patterns of inappropriate antimicrobial use in surgical and medical units at a tertiary care hospital in Switzerland: a prevalence survey. *PLoS One* 2010;5:e14011.
 15. Dorner M, Zucol F, Alessi D, Haerle SK, Bossart W, Weber M, Byland R, Bernasconi M, Berger C, Tugizov S, Speck RF, Nadal D. beta1 integrin expression increases susceptibility of memory B cells to Epstein-Barr virus infection. *J Virol* 2010;84:6667-77.
 16. Drogan D, Rauch P, Hoffmann D, Walter H, Metzner KJ. The antiretroviral potency of emtricitabine is approximately 3-fold higher compared to lamivudine in dual human immunodeficiency virus type 1 infection / competition experiments in vitro. *Antiviral Res* 2010;86:312-5.
 17. Dunn D, von Wyl V, Price H, Asboe D. The impact of the O-0 cell on measures of amino acid covariation. *AIDS* 2010;24:159-60.
 18. Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Weber R, Battegay M. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. *Arch Intern Med* 2010;170:57-65.
 19. Fehr JS, Bloemberg GV, Ritter C, Hombach M, Luscher TF, Weber R, Keller PM. Septicemia caused by tick-borne bacterial pathogen *Candidatus Neohhrlichia mikurensis*. *Emerg Infect Dis* 2010;16:1127-9.
 20. Ferry T, Hirschel B, Dang T, Meylan P, Delhumeau C, Rauch A, Weber R, Elzi L, Bernasconi E, Schmid P, Calmy A. Infrequent replication of parvovirus B19 and erythrovirus genotypes 2 and 3 among HIV-infected patients with chronic anemia. *Clin Infect Dis* 2010;50:115-8.

21. Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M, Bouchardy C, Dehler S, Jundt G, Ess S, Bordoni A, Konzelmann I, Frick H, Dal Maso L, Elzi L, Furrer H, Calmy A, Cavassini M, Ledergerber B, Keiser O. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. *Br J Cancer* 2010;103:416-22.
22. Friis-Moller N, Thiebaut R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. *Eur J Cardiovasc Prev Rehabil* 2010;17:491-501.
23. Gianella S, Haeberli L, Joos B, Ledergerber B, Wuthrich RP, Weber R, Kuster H, Hauser PM, Fehr T, Mueller NJ. Molecular evidence of interhuman transmission in an outbreak of *Pneumocystis jirovecii* pneumonia among renal transplant recipients. *Transpl Infect Dis* 2010;12:1-10.
24. Gilomen S, Ruef C, Held L, Cathomas A, French LE, Hafner J. Successful control of methicillin-resistant *Staphylococcus aureus* outbreak at a university department of dermatology. *J Eur Acad Dermatol Venereol* 2010. [Epub ahead of print].
25. Glass TR, Battegay M, Cavassini M, De Geest S, Furrer H, Vernazza PL, Hirschel B, Bernasconi E, Rickenbach M, Gunthard HF, Bucher HC. Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. *J Acquir Immune Defic Syndr* 2010;54:197-203.
26. Gran JM, Roysland K, Wolbers M, Didelez V, Sterne JA, Ledergerber B, Furrer H, von Wyl V, Aalen OO. A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study. *Stat Med* 2010;29:2757-68.
27. Gutmann C, Cusini A, Gunthard HF, Fux C, Hirschel B, Decosterd LA, Cavassini M, Yerly S, Vernazza PL. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. *AIDS* 2010;24:2347-54.
28. Haas A, Rehr M, Graw F, Rusert P, Bossart W, Kuster H, Trkola A, Gunthard HF, Oxenius A. HIV-1 replication activates CD4+ T cells with specificities for persistent herpes viruses. *EMBO Mol Med* 2010;2:231-44.
29. Hasse B, Ledergerber B, Hirschel B, Vernazza P, Glass TR, Jeannin A, Evison JM, Elzi L, Cavassini M, Bernasconi E, Nicca D, Weber R. Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study. *Clin Infect Dis* 2010;51:1314-22.
30. Hauser PM, Nahimana A, Taffe P, Weber R, Francioli P, Bille J, Rabodonirina M. Interhuman transmission as a potential key parameter for geographical variation in the prevalence of *Pneumocystis jirovecii* dihydropteroate synthase mutations. *Clin Infect Dis* 2010;51:e28-33.

31. Hofer U, Schlaepfer E, Baenziger S, Nischang M, Regenass S, Schwendener R, Kempf W, Nadal D, Speck RF. Inadequate clearance of translocated bacterial products in HIV-infected humanized mice. *PLoS Pathog* 2010;6:e1000867.
32. Joos B, Rieder P, Fischer M, Kuster H, Rusert P, Trkola A, Pillai SK, Wong JK, Weber R, Gunthard HF. Association between specific HIV-1 Env traits and virologic control in vivo. *Infect Genet Evol* 2010;10:365-72.
33. Kaur SJ, Nerlich A, Bergmann S, Rohde M, Fulde M, Zahner D, Hanski E, Zinkernagel A, Nizet V, Chhatwal GS, Talay SR. The CXC chemokine-degrading protease SpyCep of *Streptococcus pyogenes* promotes its uptake into endothelial cells. *J Biol Chem* 2010;285:27798-805.
34. Keiser O, Spoerri A, Brinkhof MW, Hasse B, Gayet-Ageron A, Tissot F, Christen A, Battegay M, Schmid P, Bernasconi E, Egger M. Suicide in HIV-infected individuals and the general population in Switzerland, 1988-2008. *Am J Psychiatry* 2010;167:143-50.
35. Keller PM, Rampini SK, Buchler AC, Eich G, Wanner RM, Speck RF, Bottger EC, Bloemberg GV. Recognition of potentially novel human disease-associated pathogens by implementation of systematic 16S rRNA gene sequencing in the diagnostic laboratory. *J Clin Microbiol* 2010;48:3397-402.
36. Knoepfel SA, Di Giallonardo F, Daumer M, Thielen A, Metzner KJ. In-depth analysis of G-to-A hypermutation rate in HIV-1 env DNA induced by endogenous APOBEC3 proteins using massively parallel sequencing. *J Virol Methods* 2010. [Epub ahead of print].
37. Kouyos RD, von Wyl V, Yerly S, Boni J, Taffe P, Shah C, Burgisser P, Klimkait T, Weber R, Hirschel B, Cavassini M, Furrer H, Battegay M, Vernazza PL, Bernasconi E, Rickenbach M, Ledergerber B, Bonhoeffer S, Gunthard HF. Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. *J Infect Dis* 2010;201:1488-97.
38. Kovari H, Ledergerber B, Battegay M, Rauch A, Hirschel B, Foguena AK, Vernazza P, Bernasconi E, Mueller NJ, Weber R. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus co-infection. *Clin Infect Dis* 2010;50:502-11.
39. Kurupati P, Turner CE, Tziona I, Lawrenson RA, Alam FM, Nohadani M, Stamp GW, Zinkernagel AS, Nizet V, Edwards RJ, Srisikandan S. Chemokine-cleaving *Streptococcus pyogenes* protease SpyCEP is necessary and sufficient for bacterial dissemination within soft tissues and the respiratory tract. *Mol Microbiol* 2010;76:1387-97.
40. Kuster SP, Hasse B, Huebner V, Bansal V, Zbinden R, Rued C, Ledergerber B, Weber R. Risk factors for infections with extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* at a tertiary care university hospital in Switzerland 2005-2007. *Infection* 2010;38:33-40.
41. Ledergerber B, Cavassini M, Battegay M, Bernasconi E, Vernazza P, Hirschel B, Furrer H, Rickenbach M, Weber R. Trends over time of virological and

immunological characteristics in the Swiss HIV Cohort Study. *HIV Med* 2010. [Epub ahead of print]

42. Lodwick R, Costagliola D, Reiss P, Torti C, Teira R, Dorrucchi M, Ledergerber B, Mocroft A, Podzamczar D, Cozzi-Lepri A, Obel N, Masquelier B, Staszewski S, Garcia F, De Wit S, Castagna A, Antinori A, Judd A, Ghosn J, Touloumi G, Mussini C, Duval X, Ramos J, Meyer L, Warszawski J, Thorne C, Masip J, Perez-Hoyos S, Pillay D, van Sighem A, Lo Caputo S, Gunthard H, Paredes R, De Luca A, Paraskevis D, Fabre-Colin C, Kjaer J, Chene G, Lundgren JD, Phillips AN. Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. *Arch Intern Med* 2010;170:410-9.
43. Lodwick RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, Khaykin P, Mocroft A, Jacobson L, De Wit S, Obel N, Castagna A, Wasmoth JC, Gill J, Klein MB, Gange S, Riera M, Mussini C, Gutierrez F, Touloumi G, Carrieri P, Guest JL, Brockmeyer NH, Phillips AN. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. *Lancet* 2010;376:340-5.
44. Lubomirov R, di Iulio J, Fayet A, Colombo S, Martinez R, Marzolini C, Furrer H, Vernazza P, Calmy A, Cavassini M, Ledergerber B, Rentsch K, Descombes P, Buclin T, Decosterd LA, Csajka C, Telenti A. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. *Pharmacogenet Genomics* 2010;20:217-30.
45. Magenta L, Dell-Kuster S, Richter WO, Young J, Hasse B, Flepp M, Hirschel B, Vernazza P, Evison J, Cavassini M, Decosterd LA, Bucher HC, Bernasconi E. Lipid and lipoprotein profile in HIV-Infected patients treated with Lopinavir/Ritonavir as a component of the first combination antiretroviral therapy. *AIDS Res Hum Retroviruses* 2010. [Epub ahead of print]
46. Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, Chave JP, Cavassini M, Bernasconi E, Calmy A, Vernazza P, Khoo S, Ledergerber B, Back D, Battegay M. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. *Antivir Ther* 2010;15:413-23.
47. Metzner KJ, Rauch P, Braun P, Knechten H, Ehret R, Korn K, Kaiser R, Sichtig N, Ranneberg B, van Lunzen J, Walter H. Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naive patients. *J Clin Virol* 2010. [Epub ahead of print]
48. Metzner KJ, Rauch P, von Wyl V, Leemann C, Grube C, Kuster H, Boni J, Weber R, Gunthard HF. Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. *J Infect Dis* 2010;201:1063-71.
49. Millard AL, Haberli L, Sinzger C, Ghielmetti M, Schneider MK, Bossart W, Seebach JD, Mueller NJ. Efficiency of porcine endothelial cell infection with human cytomegalovirus depends on both virus tropism and endothelial cell vascular origin. *Xenotransplantation* 2010;17:274-87.

50. Millard AL, Spirig R, Mueller NJ, Seebach JD, Rieben R. Inhibition of direct and indirect TLR-mediated activation of human NK cells by low molecular weight dextran sulfate. *Mol Immunol* 2010;47:2349-58.
51. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. *AIDS* 2010;24:1667-78.
52. Mocroft A, Phillips AN, Ledergerber B, Smith C, Bogner JR, Lacombe K, Wiercinska-Drapalo A, Reiss P, Kirk O, Lundgren JD. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. *Antivir Ther* 2010;15:563-70.
53. Mocroft A, Reiss P, Gasiowski J, Ledergerber B, Kowalska J, Chiesi A, Gatell J, Rakhmanova A, Johnson M, Kirk O, Lundgren J. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. *J Acquir Immune Defic Syndr* 2010;55:262-70.
54. Mueller NJ, Fux CA, Ledergerber B, Elzi L, Schmid P, Dang T, Magenta L, Calmy A, Vergopoulos A, Bischoff-Ferrari HA. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. *AIDS* 2010;24:1127-34.
55. Nicoletti J, Kuster SP, Sulser T, Zbinden R, Ruff C, Ledergerber B, Weber R. Risk factors for urinary tract infections due to ciprofloxacin-resistant *Escherichia coli* in a tertiary care urology department in Switzerland. *Swiss Med Wkly* 2010;140:w13059.
56. Opravil M, Klimkait T, Louvel S, Wolf E, Battegay M, Fux CA, Bernasconi E, Vogel M, Speck R, Weber R. Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection. *J Acquir Immune Defic Syndr* 2010;54:51-8.
57. Osih RB, Taffe P, Rickenbach M, Gayet-Ageron A, Elzi L, Fux C, Opravil M, Bernasconi E, Schmid P, Gunthard HF, Cavassini M. Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study. *AIDS Res Hum Retroviruses* 2010;26:1239-46.
58. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Gunthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Mullhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. *Gastroenterology* 2010;138:1338-45, 45 e1-7.
59. Reekie J, Mocroft A, Ledergerber B, Beniowski M, Clotet B, van Lunzen J, Chiesi A, Pradier C, Machala L, Lundgren JD. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change. *HIV Med* 2010;11:469-78.

60. Reekie J, Reiss P, Ledergerber B, Sedlacek D, Parczewski M, Gatell J, Katlama C, Fatkenheuer G, Lundgren JD, Mocroft A. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. *HIV Med* 2010. [Epub ahead of print]
61. Rieder P, Joos B, von Wyl V, Kuster H, Grube C, Leemann C, Boni J, Yerly S, Klimkait T, Burgisser P, Weber R, Fischer M, Gunthard HF. HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. *AIDS* 2010;24:1177-83.
62. Rohrbach J, Robinson N, Harcourt G, Hammond E, Gaudieri S, Gorgievski M, Telenti A, Keiser O, Gunthard HF, Hirschel B, Hoffmann M, Bernasconi E, Battegay M, Furrer H, Klenerman P, Rauch A. Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. *Gut* 2010;59:1252-8.
63. Rotger M, Dang KK, Fellay J, Heinzen EL, Feng S, Descombes P, Shianna KV, Ge D, Gunthard HF, Goldstein DB, Telenti A. Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals. *PLoS Pathog* 2010;6:e1000781.
64. Rotger M, Gsponer T, Martinez R, Taffe P, Elzi L, Vernazza P, Cavassini M, Bernasconi E, Hirschel B, Furrer H, Weber R, Ledergerber B, Egger M, Telenti A, Tarr PE. Impact of single nucleotide polymorphisms and of clinical risk factors on new-onset diabetes mellitus in HIV-infected individuals. *Clin Infect Dis* 2010;51:1090-8.
65. Sax H, Uçkay I, Balmelli C, Bernasconi E, Boubaker K, Mühlemann K, Ruef C, Troillet N, Widmer AF, Zanetti G, Pittet D. Overall burden of healthcare-associated infections among surgical patients: Results of a National Study. *Ann Surg* 2010. [Epub ahead of print].
66. Scherrer AU, von Wyl V, Fux CA, Opravil M, Bucher HC, Fayet A, Decosterd LA, Hirschel B, Khanlari B, Yerly S, Klimkait T, Furrer H, Ledergerber B, Gunthard HF. Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures. *J Acquir Immune Defic Syndr* 2010;53:464-71.
67. Schlagenhaut P, Chen LH, Wilson ME, Freedman DO, Tcheng D, Schwartz E, Pandey P, Weber R, Nadal D, Berger C, von Sonnenburg F, Keystone J, Leder K. Sex and gender differences in travel-associated disease. *Clin Infect Dis* 2010;50:826-32.
68. Schmid A, Gianella S, von Wyl V, Metzner KJ, Scherrer AU, Niederost B, Althaus CF, Rieder P, Grube C, Joos B, Weber R, Fischer M, Gunthard HF. Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. *PLoS One* 2010;5:e13310.
69. Schorn R, Hohne M, Meerbach A, Bossart W, Wuthrich RP, Schreier E, Muller NJ, Fehr T. Chronic norovirus infection after kidney transplantation: molecular evidence for immune-driven viral evolution. *Clin Infect Dis* 2010;51:307-14.

70. Smith C, Sabin C, Lundgren J, Thiebaut R, Weber R, Law M, D'Arminio Monforte A, Kirk O, Friis-Moller N, Phillips A, Reissg P, El-Sadr W, Pradier C, Worm SW. Factors associated with specific causes of death amongst HIVpositive individuals in the D:A:D study. *AIDS* 2010;24:1537-48.
71. Sullivan SG, Hirsch HH, Franceschi S, Steffen I, Amari EB, Mueller NJ, Magkouras I, Biggar RJ, Rickenbach M, Clifford GM. Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study. *AIDS* 2010;24:2245-52.
72. Thurnheer MC, Weber R, Toutous-Trellu L, Cavassini M, Elzi L, Schmid P, Bernasconi E, Christen AB, Zwahlen M, Furrer H. Occurrence, risk factors, diagnosis and treatment of syphilis in the prospective observational Swiss HIV Cohort Study. *AIDS* 2010;24:1907-16.
73. Vavricka SR, Tutuian R, Imhof A, Wildi S, Gubler C, Fruehauf H, Ruef C, Schoepfer AM, Fried M. Air suctioning during colon biopsy forceps removal reduces bacterial air contamination in the endoscopy suite. *Endoscopy* 2010;42:736-41.
74. von Wyl V, Ehteshami M, Demeter LM, Burgisser P, Nijhuis M, Symons J, Yerly S, Boni J, Klimkait T, Schuurman R, Ledergerber B, Gotte M, Gunthard HF. HIV- 1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy. *Clin Infect Dis* 2010;51:620-8.
75. von Wyl V, Ehteshami M, Symons J, Burgisser P, Nijhuis M, Demeter LM, Yerly S, Boni J, Klimkait T, Schuurman R, Ledergerber B, Gotte M, Gunthard HF. Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase. *J Infect Dis* 2010;201:1054-62.
76. Weber R, Sabin C, Reiss P, de Wit S, Worm SW, Law M, Dabis F, D'Arminio Monforte A, Fontas E, El-Sadr W, Kirk O, Rickenbach M, Phillips A, Ledergerber B, Lundgren J. HBV or HCV coinfections and risk of myocardial infarction in HIVinfected individuals: the D:A:D Cohort Study. *Antivir Ther* 2010;15:1077-86.
77. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis-Moller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren J. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. *J Infect Dis* 2010;201:318-30.
78. Young J, Scherrer A, Gunthard H, Opravil M, Yerly S, Boni J, Rickenbach M, Fux C, Cavassini M, Bernasconi E, Vernazza P, Hirschel B, Battegay M, Bucher H. Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. *HIV Med* 2010. [Epub ahead of print]

79. Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, Duan L, Choi AL, Girling V, Ho T, Li P, Fujimoto K, Lampiris H, Hare CB, Pandori M, Haase AT, Gunthard HF, Fischer M, Shergill AK, McQuaid K, Havlir DV, Wong JK. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. *J Infect Dis* 2010;202:1553-61.
80. Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, Hare CB, Pandori M, Sinclair E, Gunthard HF, Fischer M, Wong JK, Havlir DV. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. *AIDS* 2010;24:2451-60.
81. Zauner L, Melroe GT, Sigrist JA, Rechsteiner MP, Dorner M, Arnold M, Berger C, Bernasconi M, Schaefer BW, Speck RF, Nadal D. TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification. *Oncogene* 2010;29:4588-98.
82. Znoj HJ, Messerli-Burgy N, Tschopp S, Weber R, Christen L, Christen S, Grawe K. Psychotherapeutic process of cognitive-behavioral intervention in HIV-infected persons: results from a controlled, randomized prospective clinical trial. *Psychother Res* 2010;20:203-13.

Buchkapitel

1. Weber R. Intestinal coccidia and microsporidia, p. 1876-84. In: Cohen J, Powderly WG (eds.) *Infectious Diseases*, 3rd Edition. Mosby Elsevier, London 2010.

Case Reports

1. Braun D, Horovitz A, Berteau M, Jenni R, Gunthard HF. Aortic homograft endocarditis caused by *Cardiobacterium hominis* and complicated by agranulocytosis due to ceftriaxone. *BMJ Case Reports* 2010:1-4.
2. Broz P, Jacob AL, Fehr J, Kissel CK. An unusual presentation of amebic liver abscesses. *CMAJ* 2010;182:1755-7.
3. Cusini A, Gunthard HF, Stussi G, Schwarz U, Fehr T, Grueter E, Meerbach A, Bossart W, Schaer DJ, Rudiger A. Hemophagocytic syndrome caused by primary herpes simplex virus 1 infection: report of a first case. *Infection* 2010;38:423-6.
4. Flammer Anikpeh Y, Keller P, Bloemberg GV, Grünenfelder J, Zinkernagel A. Spacecraft bacterium, *Paenibacillus pasadenensis*, causing wound infection in humans. *BMJ Case Reports* 2010:1-3.
5. Hasler S, Grimm F, Thiel MA, Muller NJ, Eberhard R, Bosch MM. Swiss patient with a subconjunctival *Dirofilaria repens*. *Klin Monbl Augenheilkd* 2010;227:332-3.
6. Herold MA, Gunthard HF. [Cushing syndrome after steroid-infiltration in two HIV-patients with antiretroviral therapy]. *Praxis (Bern 1994)* 2010;99:863-5.

7. Huber M, Kovari H, Weber R, Meerbach A. Der besondere Fall: Eine besondere Gelbsucht. *Swiss Medical Forum* 2010;10:450-1.
8. Huber M, Weber R, Beck B, Schweiger A, Grimm F. Der besondere Fall: Metastasenleber mit Eosinophilie. *Swiss Medical Forum* 2010;10:687-8.
9. Kocher C, Weber R, Friedl A. A case study of female genital tuberculosis in a Western European setting. *Infection* 2010. [Epub ahead of print]
10. Kovari H, Ebnother C, Schweiger A, Berther N, Kuster H, Gunthard HF. Pulmonary toxoplasmosis, a rare but severe manifestation of a common opportunistic infection in late HIV presenters: report of two cases. *Infection* 2010;38:141-4.
11. Lucke K, Kuster SP, Berteau M, Ruef C, Bloemberg GV. A deep sternal wound infection caused by *Ureaplasma urealyticum*. *J Med Microbiol* 2010;59:1254-6.
12. Mueller NJ, Weisser M, Fehr T, Wuthrich RP, Mullhaupt B, Lehmann R, Imhof A, Aubert JD, Genoni M, Kunz R, Weber M, Steiger J. Donor-derived aspergillosis from use of a solid organ recipient as a multiorgan donor. *Transpl Infect Dis* 2010;12:54-9.

Übersichtsartikel / Reviews

1. Anagnostopoulos A, Zbinden R, Speck R. [Extended spectrum beta lactamase forming bacteria--an increasing and serious problem in ambulatory medicine]. *Praxis (Bern 1994)* 2010;99:753-65; quiz 64.
2. Colombo C, Ledergerber B, Zysset F, Francioli P, Cavassini M, Ruef C. HIV-, HBV und HCV-Expositionen im medizinischen Bereich in der Schweiz von 2001 bis Ende Juni 2008. *BAG Bulletin* 2010:36-42.
3. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. Update of the Drug Resistance Mutations in HIV-1: December 2010. *Top HIV Med* 2010;18:156-63.
4. Kaiser P, Weber R, Rampini SK. [Acute sore throat]. *Praxis (Bern 1994)* 2010;99:687-99.
5. Kotton C, Kumar D, Caliendo A, Asberg A, Chou S, Snyderman D, Allen U, Humar A. International Consensus Guidelines on the Management of Cytomegalovirus in solid organ transplantation. *Transplantation Society International CMV Consensus Group (Müller N.) Transplantation* 2010;89:779-95.
6. Millard AL, Mueller NJ. Critical issues related to porcine xenograft exposure to human viruses: lessons from allotransplantation. *Curr Opin Organ Transplant* 2010;15:230-5.
7. Millard AL, Mueller NJ. Can human viruses infect porcine xenografts? *Xenotransplantation* 2010;17:6-10.

8. Schoeni-Affolter F, Ledergerber B, Rickenbach M, Rudin C, Gunthard HF, Telenti A, Furrer H, Yerly S, Francioli P. Cohort profile: the Swiss HIV Cohort study. *Int J Epidemiol* 2010;39:1179-89.
9. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Gunthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. *JAMA* 2010;304:321-33.

Editorials

1. Ruef C. Infection control measures to prevent the transmission of nosocomial pathogens: can or should there be an international consensus? *Infection* 2010;38:157-8.
2. Ruef C. Prosthetic joint infections: what to do if the C-reactive protein level remains elevated. *Infection* 2010;38:257. 3. Ruef C. Turning hand hygiene into a habit: the need is obvious. *Infection* 2010;38:347.
4. Ruef C. Delayed diagnosis of tuberculosis. *Infection* 2010;38:431-2.

Andere Arbeiten

1. Kovari H, Ledergerber B, Weber R. Idiopathic portal hypertension in HIV-infected patients. Letter Reply. *Clin Infect Dis* 2010;50:128-9.
2. Kovari H, Ledergerber B, Weber R. Should HIV-infected patients with unexplained chronic liver enzyme elevations be tested for hepatitis E virus? *Clin Infect Dis* 2010;50:1546-7.
3. Pittet D, Allegranzi B, Chraïti M-N, Sax H, Ruef C. "Clean Care is Safer Care": Die WHO widmet den ersten globalen "Challenge" für die Patientensicherheit der Infektionsprävention. *Swiss-NOSO Bulletin* 2010;16:2-7.
4. Thompson MA, Guenthard HF, Schooley RT. In Reply to 2010 Guidelines for Antiretroviral Treatment of HIV from the International AIDS Society-USA Panel. *JAMA* 2010;304:1897-8.

Dissertationen

1. Braun D. Einfluss eines neu angestellten Infektiologen auf die Behandlung von *Staphylococcus aureus* Bakteriämien an einem Kantonsspital. Dissertation an der Universität Zürich, 2010.
2. Hübner V. Case Control Study on Risk Factors for and Clinical Outcome of Infections with Extended Spectrum Beta-Lactamase Producing *Escherichia coli* and *Klebsiella pneumoniae* in Zurich, Switzerland 2005-2007. Dissertation an der Universität Zürich, 2010.
3. Kuhn N. Retrospektive Analyse von Gebrauch und Kosten antimikrobieller Substanzen im stationären Bereich am Universitätsspital Zürich 2009. Dissertation an der Universität Zürich, 2010.